CBIO FY 2012 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$334M

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+300.0% YoY

Gross Profit

$15M100.0% margin

Operating Income

$4M23.8% margin

Net Income

$4M24.0% margin

EPS (Diluted)

$3.06

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$415,208

Balance Sheet

Total Assets

$18M

Total Liabilities

$6M

Stockholders' Equity

$13M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$4M	+300.0%
Gross Profit	$15M	$4M	+309.0%
Operating Income	$4M	-$6M	+159.7%
Net Income	$4M	-$6M	+159.8%